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Many complex biological programs are controlled at the level of gene transcription by DNA binding transcription factors.
Recent studies have revealed a novel mode of regulation by coactivator proteins, best illustrated by the PGC-1 family of
coactivators. These factors are highly responsive to a variety of environmental cues, from temperature to nutritional status
to physical activity, and they coordinately regulate metabolic pathways and biological processes in a tissue-specific man-
ner. Notably, the PGC-1 coactivators play a critical role in the maintenance of glucose, lipid, and energy homeostasis and
are likely involved in the pathogenic conditions such as obesity, diabetes, neurodegeneration, and cardiomyopathy. These
actions also raise new opportunities for the development of novel therapeutics.Transcription factors function through the docking of specific
coactivator or corepressor proteins. While transcription factors
bind to DNA in a sequence-specific fashion, they generally lack
the enzymatic activities necessary to modify chromatin, un-
wind DNA, and recruit RNA polymerase II. These biochemical
activities are the job of coregulators, which usually exist as
multiprotein complexes in the nucleus, and can be recruited to
transcription factors in response to cellular signals. Until re-
cently, most studies of biological processes controlled at the
transcriptional level have focused on changes in the amounts
or activities of transcription factors. While this is undoubtedly
a major mode of regulation, it has become very clear that tran-
scriptional coactivator proteins can be highly regulated and
can, in fact, be the primary targets of hormonal control and
signal transduction pathways (Spiegelman and Heinrich, 2004).
Perhaps the best examples of this are the PGC-1 (PPARγ co-
activator-1) coactivators. While these proteins were not the first
coactivators shown to be highly regulated, their regulation and
biological function have been studied in greatest detail. In fact,
the PGC-1 family of coactivators has emerged as major players
that integrate signaling pathways in the control of cellular and
systemic metabolism. The role of the PGC-1 coactivators in
the regulation of mitochondrial oxidative metabolism and the
maintenance of glucose, lipid, and energy homeostasis will be
discussed in this review.
The first member of the PGC-1 family was identified as a
PPARγ-interacting protein from brown fat and is now termed
PGC-1α (Puigserver et al., 1998). PGC-1β is the closest homo-
log of PGC-1α and shares extensive sequence identity (Kress-
ler et al., 2002; Lin et al., 2002a), clustered in several distinct
domains (Figures 1A and 1B), including an N-terminal activa-
tion domain (40%), a central regulatory domain (35%), and a
C-terminal RNA binding domain (48%). PGC-related coactiva-
tor (PRC) has more limited homology (Andersson and
Scarpulla, 2001), including the activation domain and RNA
binding domain. Sequence analysis reveals that the PGC-1
family of coactivators is conserved in many chordate species,
including primates, rodents, ruminants, birds, amphibians, and
fishes (Figure 2). These coactivators have similar domain struc-
ture and several signature motifs, most notably TPPTTPP andCELL METABOLISM : JUNE 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVDHDYCQ (Lin et al., 2002a), that are present in all family mem-
bers. To date, no clear PGC-1 homolog has been found in
lower eukaryotes including worm, fly, and yeast.
The PGC-1 coactivators have powerful transcriptional activ-
ity when linked to a heterologous DNA binding domain (Knutti
et al., 2000; Lin et al., 2002a; Puigserver et al., 1998), or when
they dock on a transcription factor. While they have not been
found to encode any histone acetyltransferase (HAT) activities
in their primary sequence, they bind several powerful HAT-con-
taining proteins at their N-terminal regions, including CBP,
p300, and SRC-1 (Puigserver et al., 1999). These proteins acet-
ylate histones and remodel chromatin structure to allow access
of additional factors for gene activation (Figure 1B). In addition,
several proteins encompassing the mediator complex (also
known as the TRAP/DRIP complex) dock in the C-terminal re-
gion of PGC-1α (Wallberg et al., 2003). This region also harbors
a Ser/Arg-rich domain and an RNA binding domain and has
been shown to couple pre-mRNA splicing with transcription
(Monsalve et al., 2000). The PGC-1α transcriptional activator
complex is able to displace repressor proteins, such as histone
deacetylase and small heterodimer partner (SHP), on its target
promoters, leading to augmented gene transcription (Borgius
et al., 2002; Guan et al., 2005).
A critical aspect of the PGC-1 coactivators is that they are
highly versatile and have the ability to interact with many dif-
ferent transcription factors (Table 1); in doing so, they activate
distinct biological programs in different tissues. PGC-1α, for
example, can bind to and coactivate most members of the
nuclear receptor family—often in a ligand-dependent manner
(such as the ER) but sometimes without the addition of a li-
gand, such as with PPARγ (Puigserver and Spiegelman, 2003).
PGC-1 also targets transcription factors outside of the nuclear
receptor superfamily, such as SREBP (Lin et al., 2005), FOXO1
(Puigserver et al., 2003), and Sox9 (Kawakami et al., 2005).
Table 1 summarizes transcription factor targets of PGC-1α and
β and their respective roles in mediating certain aspects of
PGC-1 function. Many of these proteins dock in a central re-
gion between the N-terminal activation domain and the C-ter-
minal SR and RNA binding domains. In addition, PGC-1α has
three functional LXXLL motifs that are used for the binding ofIER INC. DOI 10.1016/j.cmet.2005.05.004 361
R E V I E WFigure 1. Structure and function of the PGC-1 family coactivators
A) Sequence homology of PGC-1α, PGC-1β, and PRC. Note that activation do-
main (red), Arg/Ser-rich domain (yellow), and RNA binding domain (purple) are
present in all three PGC-1 family members. PGC-1α and PGC-1β share an addi-
tional domain of similarity in the central region.
B) Protein complexes associated with PGC-1α. PGC-1α binds to the HAT and
TRAP/DRIP/Mediator complexes at the amino and carboxyl termini, respectively.
SirT1 and p160 bind to the repression domain, which also contains three p38
MAP kinase phosphorylation sites. LXXLL and LLXXL denote nuclear receptor
binding sites.many nuclear receptors (Knutti et al., 2000; Puigserver et al.,
1998). The fact that PGC-1α and β contain distinct binding
sites for different transcription factors raises the interesting
possibility that alleles can be made experimentally, or may ex-
ist naturally, that can carry out only a subset of functions that
the full-length proteins can stimulate. In fact, both PGC-1α and
β mRNAs are alternatively spliced to generate multiple iso-
forms, though the functional significance of this remains un-
known (Baar et al., 2002; Kamei et al., 2003; Meirhaeghe et
al., 2003).
Regulation of mitochondrial oxidative
metabolism by PGC-1
Of the transcription factors that PGC-1α and β coactivate, one
subset draws special attention; this includes NRF-1 and
NRF-2 (Wu et al., 1999) and the nuclear hormone receptors,
such as PPARα (Vega et al., 2000), PPARδ (Wang et al., 2003),
ERRα (Huss et al., 2002; Huss et al., 2004; Kamei et al., 2003;
Mootha et al., 2004; Schreiber et al., 2004), and TR (Zhang et
al., 2004b) (Table 1). All of these transcription factors directly
regulate the expression of certain nuclear-encoded mitochon-
drial genes and were discussed in greater detail in two recent
reviews (Kelly and Scarpulla, 2004; Puigserver and Spiegel-
man, 2003). NRF-1 and 2 are themselves targets of PGC-1α
(Wu et al., 1999) and are able to stimulate the expression of
mitochondrial transcription factor A (Tfam), a mitochondrial
matrix protein essential for the replication and transcription of
mitochondrial DNA (Clayton, 1991; Parisi and Clayton, 1991;
Virbasius and Scarpulla, 1994). The simultaneous stimulation362Figure 2. Conservation of the PGC-1 family of coactivators in vertebrates
Amino acid sequences of the PGC-1 family of coactivators currently available in
the GenBank database are aligned using the Clustal program. The relative dis-
tance represents the degree of sequence identity among different members. Note
that the absence of certain members in some species is likely due to the lack of
full-length cDNA sequences in available databases.by PGC-1α and β of mitochondrial genes encoded by the two
genomes leads to increased enzymatic capacity for fatty-acid
β-oxidation, Krebs cycle, and oxidative phosphorylation
(OXPHOS). Importantly, PGC-1α and β also induce the expres-
sion of genes involved in heme biosynthesis, ion transport,
mitochondrial translation, and protein import and can stimulate
mitochondrial biogenesis and increased respiratory function
(St-Pierre et al., 2003; Wu et al., 1999). These two coactivators
stimulate the biogenesis of mitochondria with different meta-
bolic characteristics, reflecting the fact that they regulate the
expression of overlapping but distinct sets of mitochondrial
genes. For example, respiration stimulated by PGC-1β is more
highly coupled than that induced by PGC-1α, when they are
expressed in differentiated C2C12 myotubes (St-Pierre et al.,
2003). Thus, modulating the relative activity of PGC-1α and β
within the cell may lead to fine-tuning of mitochondrial function
in response to specific metabolic needs.
Recent studies in PGC-1α-deficient mice reveal that al-
though this coactivator is dispensable for mitochondrial bio-
genesis per se, it is absolutely required for the normal expres-
sion of a large number of mitochondrial genes (Leone et al.,
2005; Lin et al., 2004). The mRNA level of these genes is quan-
titatively reduced in all tissues examined to date, including
skeletal muscle, heart, liver, brown fat, and brain. Interestingly,
although PGC-1β shares many of its target genes with PGC-
1α in gain-of-function analysis (Lin et al., 2003), it is unable to
completely compensate for the loss of PGC-1α in the normal
transcription of these genes. PGC-1β mRNA levels remain un-
altered in several tissues from PGC-1α null mice. The loss of
PGC-1α leads to significant functional deficits in oxidative me-
tabolism in multiple tissues and renders mice exercise intoler-
ant (Leone et al., 2005). Notably, AMP-dependent kinase is
constitutively activated in skeletal muscle lacking PGC-1α,
presumably reflecting a state of energy deficit (Lin et al., 2004).CELL METABOLISM : JUNE 2005
R E V I E WTable 1. Transcription factor targets of the PGC-1 coactivators
Transcription factor PGC-1α PGC-1β Function References
NRF-1 + + mitochondrial genes Wu et al., 1999
NRF-2 + ND mitochondrial genes Mootha et al., 2003
PPARα + + fatty-acid oxidation Vega et al., 2000
PPARβ/δ + ND fatty-acid oxidation Wang et al., 2003
PPARγ + + UCP1/GyK induction Guan et al., 2005; Puigserver et al., 1998
Huss et al., 2002; Huss et al., 2004; Kamei et al., 2003;
ERRα,β,γ + + mitochondrial genes Mootha et al., 2004; Schreiber et al., 2004
TRβ + + cpt-1 induction Wu et al., 2002; Zhang et al., 2004b; Shin et al., 2003
LXRα,β + + lipoprotein secretion Lin et al., 2005; Oberkofler et al., 2003
FXR + ND triglyceride metabolism Zhang et al., 2004a
GR + − gluconeogenesis Kressler et al., 2002; Yoon et al., 2001
ERα,β + + unknown Kressler et al., 2002
PXR + ND unknown Bhalla et al., 2004
Sox9 + ND chondrogenesis Kawakami et al., 2005
MEF2 + ND slow fiber genes Lin et al., 2002b; Michael et al., 2001
FOXO1 + − gluconeogenesis Puigserver et al., 2003
HNF4α + ± gluconeogenesis Lin et al., 2002a; Yoon et al., 2001
SREBP1a, 1c, 2 − + lipogenesis/ lipoprotein Lin et al., 2005
secretionThese results underscore a critical role of PGC-1α in the con-
trol of mitochondrial OXPHOS and cellular energy homeosta-
sis. Whether a switch of energy production through enhanced
glycolysis occurs in PGC-1α null mice remains to be deter-
mined.
Tissue-specific metabolic actions
of the PGC-1 coactivators
As summarized in Figure 3A, PGC-1α has been shown to regu-
late adaptive thermogenesis in brown fat (Puigserver et al., The following sections review PGC-1 function in brown fat,
Figure 3. Biological activity and regulation of
PGC-1α.
A) Tissue-specific function of PGC-1α and β. PGC-
1α regulates adaptive thermogenesis in brown fat,
muscle-fiber specification, and hepatic-fasting re-
sponse, while PGC-1β coordinates lipogenesis and
lipoprotein secretion in liver in response to dietary
fats.
B) Regulation of PGC-1α expression in skeletal
muscle and mechanisms by which PGC-1α stimu-
lates mitochondrial gene expression. Coactivation
of MEF2 by PGC-1α provides a positive feed-for-
ward signal to rapidly induce PGC-1α expression
following muscle contraction. PGC-1α induces the
expression of ERRα, which activates the expression
of NRF-1, NRF-2, and ERRα itself. These molecular
events lead to the stimulation of nuclear-encoded
mitochondrial genes. PGC-1α also simultaneously
regulates the expression of slow-twitch muscle fiber
genes through coactivation of MEF2.CELL METABOLISM : JUNE 20051998; Tiraby et al., 2003), hepatic gluconeogenesis and keto-
genesis (Herzig et al., 2001; Rhee et al., 2003; Yoon et al.,
2001), and the specification of slow-twitch muscle fibers (Lin
et al., 2002b). In contrast, PGC-1β controls hepatic lipid syn-
thesis and lipoprotein production (Lin et al., 2005). It is evident
that a major feature of PGC-1 function is their ability to stimu-
late the program of mitochondrial biogenesis while simulta-
neously modulating biological processes commonly associ-
ated with increased oxidative capacity for a particular tissue.363
R E V I E Wliver, skeletal, and cardiac muscle and brain, based on gain-
and loss-of-function analysis in cultured cells and in vivo.
Brown fat
PGC-1α was discovered as a molecular switch that turns on
several key components of the adaptive thermogenic program
in brown fat (Puigserver et al., 1998), including the stimulation
of fuel intake, mitochondrial fatty-acid oxidation, and heat
production through expression of uncoupling protein-1 (UCP1).
The expression of PGC-1α is rapidly and strongly induced by
cold exposure. Ectopic expression of PGC-1α is sufficient to
promote differentiation toward the brown-fat lineage, as shown
by activation of UCP1 expression (Puigserver et al., 1998),
even in human cells (Tiraby et al., 2003). Notably, mice deficient
in PGC-1α are extremely cold sensitive (Leone et al., 2005; Lin
et al., 2004). This is due to defective thermogenesis, likely
caused by impaired mitochondrial programs for fatty-acid
β-oxidation and electron transport, accompanied by reduced
induction of UCP1 and deiodinase 2 in brown fat. Despite this,
PGC-1α appears to be dispensable for brown adipocyte differ-
entiation. One possibility is that PGC-1β, which is induced dur-
ing brown-fat cell differentiation (Lin et al., 2002a), may play a
fundamental role in the development of brown adipocytes.
Liver
The expression of PGC-1α and β is induced in the liver at birth
and in the adult liver following fasting (Lin et al., 2003; Yoon et
al., 2001). The transition from fed to fasted states involves
drastic metabolic changes in the liver to facilitate the adapta-
tion of organisms to nutrient deprivation; these changes in-
clude activation of gluconeogenesis, fatty-acid β-oxidation,
and the synthesis and secretion of ketone bodies. A shift in
fuel usage from glucose to fats and ketone bodies by periph-
eral tissues is critical for the maintenance of systemic glucose
homeostasis and survival of organisms in periods of food
shortage. Studies in cultured hepatocytes and in vivo have
demonstrated that PGC-1α is sufficient to activate nearly all
aspects of the hepatic fasting response, including gluconeo-
genesis, fatty-acid β-oxidation, ketogenesis, and bile-acid ho-
meostasis. It does so by coactivating key hepatic transcription
factors, such as HNF4α, PPARα, GR, FOXO1, FXR and LXR,
and directly stimulating transcription from their target promot-
ers (Oberkofler et al., 2003; Puigserver et al., 2003; Rhee et al.,
2003; Shin et al., 2003; Yoon et al., 2001; Zhang et al., 2004a).
In contrast to PGC-1α, PGC-1β has a minimal effect on the
expression of gluconeogenic genes, though this factor also po-
tently enhances the expression of genes involved in fatty-acid
oxidation and ketogenesis (Lin et al., 2003). The required role
of PGC-1α in the control of hepatic gluconeogenesis has been
revealed by RNAi knockdown experiments in vivo and in ge-
netic studies using PGC-1α knockout mice (Koo et al., 2004;
Lin et al., 2004). PGC-1α deficiency clearly impairs gluco-
neogenic gene expression and hepatic glucose production and
leads to fasting hypoglycemia. In addition, mice lacking PGC-
1α develop hepatic steatosis upon fasting (Leone et al., 2005).
The physiological role of PGC-1β in the regulation of the he-
patic fasting response remains under investigation.
Recent studies have implicated PGC-1β as a key regulator
of hepatic lipogenesis and lipoprotein secretion in response to
dietary intake of saturated fats (Lin et al., 2005). Here, the ex-
pression of PGC-1β in the liver is strongly induced by dietary
fats, likely through direct regulation by fatty acids in hepato-
cytes. PGC-1β docks and coactivates the SREBP and LXR364families of transcription factors, coupling triglyceride and cho-
lesterol synthesis, lipoprotein transport, and VLDL secretion.
SREBPs are key transcription factors that control the expres-
sion of many genes that regulate fatty-acid, triglyceride (Kim
and Spiegelman, 1996; Shimano et al., 1996; Tontonoz et al.,
1993), and cholesterol biosynthesis (Brown and Goldstein,
1997), while LXRs are important in the control of lipoprotein
secretion. The crucial role of PGC-1β in mediating the link be-
tween hyperlipidemia and saturated fat intake was demon-
strated by RNAi knockdown studies in the livers of mice. Thus,
the PGC-1β signaling pathway provides a plausible link be-
tween consumption of saturated and trans fats and hyperlipid-
emia, including hypercholesterolemia.
Although the induction of PGC-1β by dietary fats is robust,
the expression of most of its mitochondrial target genes is not
elevated in response to fat intake. These results raise the inter-
esting possibility that the activities of PGC-1β in the regulation
of hepatic metabolism is strongly influenced by nutritional
status, perhaps as a result of hormonal milieu under different
physiological conditions. Similarly, although PGC-1α has been
demonstrated to coactivate a large number of transcription
factors in various cell types, it is highly unlikely that these path-
ways are simultaneously active in the presence of PGC-1α. The
molecular basis of this specificity in gene activation remains
poorly understood. It is possible that the availability of ligands
and posttranslational modification of transcription factors and/
or the PGC-1 themselves may contribute to the promoter se-
lectivity. This is a very important avenue for further inquiry.
Skeletal muscle
The ability of PGC-1α to control multiple pathways in a com-
plex biological program is also illustrated in skeletal muscle.
In this case, PGC-1α functions as a sensitive “rheostat” that
responds to neuromuscular input and the ensuing contractile
activity. The expression of PGC-1α is readily inducible by exer-
cise training in rodents and humans (Baar et al., 2002; Goto et
al., 2000; Norrbom et al., 2004). The subsequent activation of
calcium signaling pathways appears to play a major role in the
stimulation of PGC-1α transcription through calcineurin and
calcium-dependent protein kinases (Wu et al., 2002), which
culminate in the activation of several transcription factors, such
as CREB and MEF2, in a feed-forward loop (Figure 3B)
(Handschin et al., 2003). Although AMPK has been shown to
be required for exercise-induced PGC-1α expression (Zong et
al., 2002), the transcriptional targets of AMPK action on the
PGC-1α promoter are still not clear.
Ectopic expression of PGC-1α in myotubes stimulates
GLUT4 expression and mitochondrial oxidative metabolism
(Michael et al., 2001). Importantly, transgenic expression of
PGC-1α in fast-twitch muscle fibers at or near physiological
levels leads to activation of genetic programs characteristic of
slow-twitch muscle fibers (Lin et al., 2002b). The skeletal mus-
cle of these transgenic mice is resistant to contraction-induced
fatigue, indicating a functional switch of muscle fiber types by
PGC-1α. Consistent with these gain-of-function studies, PGC-
1α-deficient skeletal muscle is prone to contraction-induced
fatigue and the knockout mice are exercise intolerant (Leone
et al., 2005). Again, PGC-1α is able to couple the metabolic
and contractile arms of muscle-fiber specification and func-
tionally transforms fast-twitch fibers into more oxidative slow-
twitch fibers. It is highly likely that similar regulatory mecha-
nisms also occur in other tissues where related cell typesCELL METABOLISM : JUNE 2005
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differentiation.
Transgenic expression of PGC-1β under the control of the
β-actin promoter leads to mitochondrial biogenesis in skeletal
muscle and resistance to diet-induced obesity (Kamei et al.,
2003). However, the role of PGC-1β in the control of the meta-
bolic and contractile phenotype of skeletal muscle fibers re-
mains to be ascertained.
Heart
Both PGC-1α and β are expressed very abundantly in the heart
(Lin et al., 2002a; Puigserver et al., 1998), an organ with an
extremely high and dynamic demand for ATP. Much of this sup-
ply comes from the oxidation of fatty acids, though glucose
can also be a substrate for mitochondrial oxidation. To date,
the role of PGC-1β in cardiac energy metabolism is less well
studied, but several studies have implicated PGC-1α as a cru-
cial regulator of oxidative metabolism in the heart. PGC-1α
mRNA levels are strongly induced in the neonatal heart, along
with the activation of mitochondrial biogenesis and the meta-
bolic switch from glycolysis to fuel oxidation in cardiac muscle
(Lehman et al., 2000). Forced expression of PGC-1α in cultured
neonatal cardiomyocytes and in vivo powerfully stimulates
mitochondrial gene expression and biogenesis (Lehman et al.,
2000). In fact, very high transgenic expression of PGC-1α in
mouse heart leads to such robust mitochondrial biogenesis
that the contractile apparatus is displaced, and dilated cardio-
myopathy ensues. Interestingly, PGC-1α null mice develop
early symptoms of heart failure, such as activation of a fetal
program of cardiac gene expression and significant increase in
circulating levels of atrial natriuretic peptide, a hallmark of
cardiac dysfunction (Arany et al., 2005). Defects in cardiac
function are most clearly seen when the intact hearts were
studied in isolated perfusion chambers. Here, the PGC-1α-
deficient heart shows a significantly lower cardiac reserve in
response to electrical or chemical stimulation (Arany et al.,
2005) and is thus less able to perform work in response to
increased demand. Abnormal heart rate and impaired left ven-
tricular function were also observed in PGC-1α-deficient mice
following exercise (Leone et al., 2005).
Brain
PGC-1α deficiency leads to certain behavioral abnormalities,
including profound hyperactivity (Leone et al., 2005; Lin et al.,
2004). These behavioral changes are associated with axonal
degeneration in the brain, especially in the striatum (Lin et al.,
2004), a region known to be very important in the control of
movement. The molecular basis of this axonal degeneration is
not completely understood, though impaired energy homeo-
stasis and reactive oxygen species (ROS) metabolism due to
defects in mitochondrial function are the most likely causes.
Neurons consume large amounts of ATP to maintain their
membrane ionic gradient and axonal transport and rely almost
exclusively on oxidative metabolism to derive energy for this
function. In fact, the most common symptoms of patients with
genetic mutations of mitochondrial genes are neurological re-
lated, reflecting an extremely low tolerance for perturbing
OXPHOS in the brain (Schon and Manfredi, 2003). It cannot be
ruled out, however, that PGC-1α also regulates pathways criti-
cal for neuronal function. In fact, the expression of several neu-
rofilament proteins and the α2 subunit of sodium pumps is re-
duced in the PGC-1α null brain (Lin et al., 2004). It is not yetCELL METABOLISM : JUNE 2005clear whether this represents the cause or the effect of the ob-
vious brain lesions in the knockout mice.
PGC-1 and the metabolism of ROS
The mitochondrial electron transport chain is a major site of
ROS production in the cell (Lenaz et al., 2002; Lowell and Shul-
man, 2005). Under normal conditions, the balance between
ROS generation and detoxification is controlled by a set of cel-
lular enzymes including superoxide dismutase (SOD), catalase,
and those involved in glutathione metabolism. As PGC-1 stim-
ulate mitochondrial-based respiration, they also increase the
expression of SOD and glutathione peroxidase, as well as en-
zymes responsible for glutathione biosynthesis (St-Pierre et al.,
2003). Thus, certain components of the ROS scavenging path-
way are linked by the PGC-1 to mitochondrial oxidative metab-
olism, apparently enabling cells to maintain normal redox
status in response to changing oxidative capacity. In addition,
PGC-1α and β stimulate the expression of UCP2 and UCP3
(Puigserver et al., 2001; St-Pierre et al., 2003; Wu et al., 1999),
which dissipate the proton gradient and lower mitochondrial
membrane potential, a process thought to greatly reduce ROS
production by mitochondria (Miwa and Brand, 2003). Hence,
the PGC-1 coactivators apparently have two related but dis-
tinct mechanisms to modulate ROS metabolism in cells.
Reactive oxygen and nitrogen species are capable of trans-
ducing cellular signals under certain conditions (Soberman,
2003). However, excess free radical production leads to oxida-
tive stress, which causes DNA damage, lipid peroxidation, and
oxidative protein modifications. It is now clear that ROS gener-
ation is greatly elevated following certain metabolic perturba-
tion, such as ischemia reperfusion of the heart, stroke in the
brain, as well as a wide range of disorders including neurode-
generative diseases (Ischiropoulos and Beckman, 2003). Given
the abnormality seen in the brain and heart of PGC-1α knock-
out mice (Leone et al., 2005; Lin et al., 2004), it is highly likely
that the PGC-1 are important regulators of ROS metabolism
in normal physiological conditions and under certain states of
oxidative stress.
Regulation of PGC-1 activity
The diverse and potent effects of PGC-1α and β on cellular
energy metabolism necessitate that their activities be tightly
controlled. This, in theory, can be achieved at the transcrip-
tional and posttranscriptional levels. In fact, PGC-1α protein
has a very short half-life (w2.3 hr) and is greatly stabilized fol-
lowing phosphorylation at three sites (T262, S265, and T298)
by p38 MAP kinase (Knutti et al., 2001; Puigserver et al., 2001).
These modifications also enhance the transcriptional activity of
PGC-1α by displacing p160 myb binding protein (p160MBP), a
strong transcriptional suppressor (Fan et al., 2004). The binding
of p160 may largely account for the suppressive activity resid-
ing in the central domain of PGC-1α. Additional factors that
negatively impact PGC-1α action include PXR and SHP, which
interfere with PGC-1α recruitment to its target transcription
factors (Bhalla et al., 2004; Borgius et al., 2002).
Another protein that has been shown to modulate PGC-1α
activity is SirT1, the mammalian homolog of the yeast Sir2.
SirT1 associates with PGC-1α in the central regulatory region
between amino acids 200 and 400 and deacetylates PGC-1α,
leading to enhanced transcriptional activity in a NAD+-depen-
dent way (Rodgers et al., 2005). This is particularly interesting365
R E V I E Wbecause Sir2 regulates aging in yeast and other organisms
(Blander and Guarente, 2004); aging is a process that is af-
fected by metabolic parameters, especially caloric restriction,
in many species. The ability of SirT1 to bind to PGC-1α and
activate it makes a direct molecular connection between the
pathways that impact organismal aging and metabolic regula-
tion. An important question is whether SirT1 also modulates
the transcriptional activity of PGC-1β and PRC.
In addition to posttranslational mechanisms, many studies
have clearly demonstrated that the PGC-1 coactivators are
regulated at the transcriptional level in response to a variety of
nutritional and environmental stimuli (Figure 3A). PGC-1α and
β are abundantly expressed in tissues with high energetic need,
including brown fat, cardiac, and skeletal muscle and the
central nervous system (Kressler et al., 2002; Lin et al., 2002a;
Puigserver et al., 1998). In addition, their mRNA levels are sub-
ject to substantial regulation by physiological signals within
these tissues. For example, PGC-1α mRNA levels are rapidly
induced in brown fat following cold exposure (Puigserver et al.,
1998) and in skeletal muscle in response to bouts of exercise
(Baar et al., 2002; Goto et al., 2000); PGC-1β expression re-
mains unchanged under these conditions (Lin et al., 2002a). In
contrast, hepatic expression of PGC-1β is stimulated by di-
etary-fat intake and thyroid hormone to a much greater extent
than PGC-1α (Lin et al., 2005; Weitzel et al., 2003). The expres-
sion of both of these coactivators is increased in the neonatal
liver and heart, correlating with a dramatic expansion of oxida-
tive capacity in these tissues during early postnatal develop-
ment (Lehman et al., 2000; Lin et al., 2003). PGC-1α and β
mRNA levels are relatively low in adult liver in the fed state;
however, they are readily inducible upon brief fasting (Lin et al.,
2002a; Lin et al., 2003; Yoon et al., 2001).
Although the expression of PGC-1β is not regulated by cold
exposure, its mRNA level is increased during differentiation of
cultured brown and white adipocytes (Kamei et al., 2003; Lin
et al., 2002a). While the role of PGC-1α in adaptive thermogen-
esis has been firmly established, the function of PGC-1β in the
regulation of development and function of adipocytes remains
unexplored. Interestingly, the expression of PRC in cultured fi-
broblasts is inducible by serum treatments and is regulated in
a cell-cycle-dependent manner that peaks during the G0-to-G1
transition (Andersson and Scarpulla, 2001). Thus, it is now
clear that the expression of this entire family of coactivators is
under control by distinct extracellular signals, consistent with
the fact that they modulate different aspects of metabolism
and other biological processes in the cell.
Activation of the cAMP signaling pathway is a major mecha-
nism underlying the induction of PGC-1α in several different
cell types. In fact, the proximal promoter of PGC-1α contains
a functional CREB binding site that is required for cAMP re-
sponse (Herzig et al., 2001). CREB integrates multiple signaling
pathways in various cell types, including glucagon action in
the fasted liver (Herzig et al., 2001), calcium signaling through
calcium/calmodulin-dependent protein kinase and calcineurin
A in exercised skeletal muscle and heart (Handschin et al.,
2003; Ojuka et al., 2003; Schaeffer et al., 2004) and adaptive
thermogenesis in brown fat (Puigserver et al., 1998). Stimula-
tion of activating transcription factor 2 (ATF2) by p38 MAP ki-
nase has also been shown to modulate the induction of PGC-
1α in brown fat by cold (Cao et al., 2004). In states of low
energy, PGC-1α can also be induced by the AMP-dependent366protein kinase (AMPK) in skeletal muscle and subsequently in-
crease energy levels by boosting oxidative metabolism (Irrcher
et al., 2003; Suwa et al., 2003; Terada et al., 2002; Zong et al.,
2002). In contrast, cyclin-dependent kinase 9 suppresses the
expression of PGC-1α and mitochondrial function in the heart,
leading to the development of cardiomyopathy (Sano et al.,
2004).
Intriguingly, some transcription factors that are coactivated
by PGC-1α can simultaneously serve as regulators of PGC-1α
transcription. This is best illustrated by the regulation of PGC-
1α expression by MEF2 in skeletal muscle (Czubryt et al., 2003;
Handschin et al., 2003). The presence of such autoregulatory
loops provides a molecular mechanism to sustain PGC-1α ex-
pression following physiological stimuli, as in the case of endu-
rance exercise (Figure 3).
PGC-1 and metabolic diseases
It is apparent now that the PGC-1 family of coactivators is
highly responsive to environmental stimuli and nutritional
states of an organism. These coactivators transduce physio-
logical and/or environmental signals and modulate programs
of gene expression in a tissue-specific manner. The major
activities of PGC-1α and β studied to date have been in the
modulation of glucose, lipid, and energy metabolism, enabling
the organisms to adapt to their fluctuating nutritional status and
environmental conditions. This adaptation to a variety of environ-
mental challenges, from temperature to nutritional changes to al-
terations in physical activity, seems to be a raison d’etre for
the PGC-1 coactivators. Abnormal PGC-1 activities might alter
metabolic properties of tissues and lead to various diseases
with underlying dysregulation of metabolism or, alternatively,
allow certain cells to thrive in their unique tissue environment,
such as during the progression of cancer.
Since the PGC-1 coactivators regulate multiple aspects of
glucose, lipid, and energy metabolism, it is not surprising that
dysregulation of these proteins has been observed in several
pathological conditions. PGC-1α mRNA levels are elevated in
the liver of rodents in models of both type 1 and type 2 diabe-
tes; this is likely due to alterations of the insulin/glucagons axis
and hepatic insulin resistance, respectively (Herzig et al., 2001;
Yoon et al., 2001). Increased PGC-1α activity clearly contrib-
utes to elevated hepatic glucose output and the development
of hyperglycemia. In fact, acute knockdown of PGC-1α in liver
improves hepatic insulin sensitivity and glucose tolerance in
db/db mice (Koo et al., 2004). Thus, modulating PGC-1α activ-
ity in the liver may have important implication for systemic glu-
cose homeostasis. PGC-1α stimulates gluconeogenic gene
expression through coactivation of GR, FOXO1, and HNF4α. It
is tempting to speculate that chemical compounds that selec-
tively disrupt the docking of PGC-1α on these gluconeogenic
transcription factors may provide a novel therapeutic modality
for the treatment of hyperglycemia (Barthel and Schmoll, 2003).
Similarly, disruption of PGC-1β docking on SREBP and LXR
may specifically lead to suppression of the lipogenic and hy-
perlipidemic activities of PGC-1β in liver. In fact, it has been
demonstrated as a proof of principle that agonist ligands for
the GR can be developed that promote docking of the coacti-
vator GRIP1 to the GR while not promoting PGC-1α docking;
these compounds have reduced hyperglycemic activity (Cogh-
lan et al., 2003).
Insulin resistance is a major pathogenic factor in the devel-CELL METABOLISM : JUNE 2005
R E V I E Wopment of type 2 diabetes. Recent evidence clearly points to
a strong association between insulin resistance and mitochon-
drial dysfunction in skeletal muscle (Lowell and Shulman,
2005). The expression of a large set of OXPHOS genes is quan-
titatively reduced in skeletal muscle from type 2 diabetic pa-
tients and insulin-resistant prediabetic individuals (Mootha et
al., 2003; Patti et al., 2003). This is accompanied by a signifi-
cant decrease in the mRNA levels of PGC-1α, PGC-1β, and
NRF-1 (Patti et al., 2003) and by abnormal mitochondrial mor-
phology (Kelley et al., 2002). Importantly, a single nucleotide
polymorphism (Gly482Ser) in human PGC-1α has been associ-
ated with insulin resistance and susceptibility to type 2 diabe-
tes in some populations (Ek et al., 2001; Hara et al., 2002;
Lacquemant et al., 2002; Muller et al., 2003). Impairment of
mitochondrial oxidative metabolism has also been observed in
age-related insulin resistance (Petersen et al., 2003). Despite
these strong associations, it is not clear whether reduced
PGC-1 expression and impaired mitochondrial OXPHOS are
causal factors in the development of insulin resistance and
type 2 diabetes. It is interesting to note that the expression of
PGC-1α and β is induced in skeletal muscle in response to
insulin (Ling et al., 2004). Hence insulin resistance per se may
lead to reduced PGC-1 expression and mitochondrial dysfunc-
tion, which may in turn aggravate insulin resistance, resulting
in a deleterious spiral. It is tempting to speculate that elevating
the activity of PGC-1 in skeletal muscle might provide benefi-
cial effects on muscle metabolism and insulin sensitivity. To-
ward this end, compounds targeting the expression of PGC-1
and/or docking of PGC-1 on certain transcription factors, such
as ERRα, PPAR, and NRF, should be developed and tested.
The regulation of PGC-1α expression in the heart suggests
a role for this protein in the control of fuel utilization, particularly
the switch from glucose to fatty-acid oxidation in neonatal de-
velopment and under physiological stresses, such as fasting
(Huss and Kelly, 2004). PGC-1α mRNA levels are elevated in
the myocardium of streptozotocin-treated and db/db mice
(Finck et al., 2002), suggesting that this coactivator may play
a role in the development of diabetic cardiomyopathy. Recent
studies indicate that PGC-1α-deficient heart has impaired oxi-
dative energy generation and decreased contractile function,
suggesting that PGC-1α is required for energy homeostasis in
cardiac muscle. The expression of PGC-1α is reduced in ani-
mal models of heart failure caused by pressure overload or
ischemia, along with PPARα and genes involved in fatty-acid
oxidation. These results would argue that the decrease of
PGC-1α mRNA in heart may represent a maladaptive response
that eventually leads to energetic failure and cardiac dysfunc-
tion. Similar to the situation in skeletal muscle, enhancing
PGC-1 activity in cardiac muscle may boost cellular oxidative
metabolism and improve contractile function of heart. In addi-
tion, PGC-1α has been shown to protect cardiomyocytes from
apoptosis (Sano et al., 2004), suggesting that there may be
additional therapeutic benefit for activating the PGC-1 pathway
in various forms of cardiomyopathy and congestive heart
failure.
Clearly, abnormal PGC-1 activity is likely to play an important
role in the pathogenesis of hyperglycemia, insulin resistance,
and cardiomyopathy. It remains to be determined whether dys-
regulation of the PGC-1 is also present in other disorders asso-
ciated with impaired mitochondrial OXPHOS and increased
oxidative stress, most notably, in various forms of neurodegen-CELL METABOLISM : JUNE 2005erative disease. More importantly, the PGC-1 pathways offer
novel targets for potential therapeutic intervention. It can be
expected that the modulation of coactivator docking on their
specific binding partners will provide opportunities to selec-
tively stimulate or suppress certain pathways, hence obtaining
desirable physiological effects. The development of ligands for
nuclear receptors which can selectively recruit certain coacti-
vators has already been demonstrated (Coghlan et al., 2003).
Thus, new classes of valuable drugs may be in the offing.
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